Literature DB >> 24532806

Increased BCR responsiveness in B cells from patients with chronic GVHD.

Jessica L Allen1, Prasanthi V Tata, Matthew S Fore, Jenna Wooten, Sharmistha Rudra, Allison M Deal, Andrew Sharf, Todd Hoffert, Philip A Roehrs, Thomas C Shea, Jonathan S Serody, Kristy L Richards, Madan Jagasia, Stephanie J Lee, David Rizzieri, Mitchell E Horwitz, Nelson J Chao, Stefanie Sarantopoulos.   

Abstract

Although B cells have emerged as important contributors to chronic graft-versus-host-disease (cGVHD) pathogenesis, the mechanisms responsible for their sustained activation remain unknown. We previously showed that patients with cGVHD have significantly increased B cell-activating factor (BAFF) levels and that their B cells are activated and resistant to apoptosis. Exogenous BAFF confers a state of immediate responsiveness to antigen stimulation in normal murine B cells. To address this in cGVHD, we studied B-cell receptor (BCR) responsiveness in 48 patients who were >1 year out from allogeneic hematopoietic stem cell transplantation (HSCT). We found that B cells from cGVHD patients had significantly increased proliferative responses to BCR stimulation along with elevated basal levels of the proximal BCR signaling components B cell linker protein (BLNK) and Syk. After initiation of BCR signaling, cGVHD B cells exhibited increased BLNK and Syk phosphorylation compared with B cells from patients without cGVHD. Blocking Syk kinase activity prevented relative post-HSCT BCR hyper-responsiveness of cGVHD B cells. These data suggest that a lowered BCR signaling threshold in cGVHD associates with increased B-cell proliferation and activation in response to antigen. We reveal a mechanism underpinning aberrant B-cell activation in cGVHD and suggest that therapeutic inhibition of the involved kinases may benefit these patients.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24532806      PMCID: PMC3968393          DOI: 10.1182/blood-2013-10-533562

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  36 in total

1.  Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans.

Authors:  Mathangi Srinivasan; Ryan Flynn; Andrew Price; Ann Ranger; Jeffrey L Browning; Patricia A Taylor; Jerome Ritz; Joseph H Antin; William J Murphy; Leo Luznik; Mark J Shlomchik; Angela Panoskaltsis-Mortari; Bruce R Blazar
Journal:  Blood       Date:  2011-11-09       Impact factor: 22.113

2.  Multiple morphea-like lesions associated with chronic graft-versus-host disease after cord blood transplantation.

Authors:  Yoshio Kawakami; Mikio Ohtsuka; Atsushi Kikuta; Toshiyuki Yamamoto
Journal:  Acta Derm Venereol       Date:  2009       Impact factor: 4.437

3.  Bone marrow B cell precursor number after allogeneic stem cell transplantation and GVHD development.

Authors:  Yuri Fedoriw; T Danielle Samulski; Allison M Deal; Cherie H Dunphy; Andrew Sharf; Thomas C Shea; Jonathan S Serody; Stefanie Sarantopoulos
Journal:  Biol Blood Marrow Transplant       Date:  2012-03-20       Impact factor: 5.742

4.  B cells from patients with chronic GVHD are activated and primed for survival via BAFF-mediated pathways.

Authors:  Jessica L Allen; Matthew S Fore; Jenna Wooten; Philip A Roehrs; Nazmim S Bhuiya; Todd Hoffert; Andrew Sharf; Allison M Deal; Paul Armistead; James Coghill; Don A Gabriel; Robert Irons; Amber Essenmacher; Thomas C Shea; Kristy Richards; Corey Cutler; Jerome Ritz; Jonathan Serody; Albert S Baldwin; Stefanie Sarantopoulos
Journal:  Blood       Date:  2012-08-14       Impact factor: 22.113

5.  Significant differences in B-cell subpopulations characterize patients with chronic graft-versus-host disease-associated dysgammaglobulinemia.

Authors:  Zoya Kuzmina; Hildegard T Greinix; Roman Weigl; Ulrike Körmöczi; Arno Rottal; Sophie Frantal; Sandra Eder; Winfried F Pickl
Journal:  Blood       Date:  2010-11-09       Impact factor: 22.113

6.  Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter, phase II study.

Authors:  Seok Jin Kim; Jong Wook Lee; Chul Won Jung; Chang Ki Min; Bin Cho; Ho Jin Shin; Joo Seop Chung; Hawk Kim; Won Sik Lee; Young Don Joo; Deok-Hwan Yang; Hoon Kook; Hyoung Jin Kang; Hyo Seop Ahn; Sung-Soo Yoon; Sang Kyun Sohn; Yoo Hong Min; Woo-Sung Min; Hee-Sook Park; Jong Ho Won
Journal:  Haematologica       Date:  2010-07-27       Impact factor: 9.941

7.  Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence.

Authors:  Sally Arai; Bita Sahaf; Balasubramanian Narasimhan; George L Chen; Carol D Jones; Robert Lowsky; Judith A Shizuru; Laura J Johnston; Ginna G Laport; Wen-Kai Weng; Jonathan E Benjamin; Joanna Schaenman; Janice Brown; Jessica Ramirez; James L Zehnder; Robert S Negrin; David B Miklos
Journal:  Blood       Date:  2012-05-04       Impact factor: 22.113

Review 8.  Advances in graft-versus-host disease biology and therapy.

Authors:  Bruce R Blazar; William J Murphy; Mehrdad Abedi
Journal:  Nat Rev Immunol       Date:  2012-05-11       Impact factor: 53.106

9.  Diverse phosphorylation patterns of B cell receptor-associated signaling in naïve and memory human B cells revealed by phosphoflow, a powerful technique to study signaling at the single cell level.

Authors:  Franklin R Toapanta; Paula J Bernal; Marcelo B Sztein
Journal:  Front Cell Infect Microbiol       Date:  2012-10-17       Impact factor: 5.293

10.  The BAFF receptor transduces survival signals by co-opting the B cell receptor signaling pathway.

Authors:  Edina Schweighoffer; Lesley Vanes; Josquin Nys; Doreen Cantrell; Scott McCleary; Nicholas Smithers; Victor L J Tybulewicz
Journal:  Immunity       Date:  2013-02-28       Impact factor: 31.745

View more
  43 in total

1.  Durable responses to ibrutinib in patients with relapsed CLL after allogeneic stem cell transplantation.

Authors:  C S Link; R Teipel; F Heidenreich; E Rücker-Braun; M Schmiedgen; J Reinhardt; U Oelschlägel; M von Bonin; J M Middeke; A Muetherig; K Trautmann-Grill; U Platzbecker; M Bornhäuser; J Schetelig
Journal:  Bone Marrow Transplant       Date:  2016-01-11       Impact factor: 5.483

2.  Neutrophil extracellular traps (NETs) contribute to pathological changes of ocular graft-vs.-host disease (oGVHD) dry eye: Implications for novel biomarkers and therapeutic strategies.

Authors:  Seungwon An; Ilangovan Raju; Bayasgalan Surenkhuu; Ji-Eun Kwon; Shilpa Gulati; Muge Karaman; Anubhav Pradeep; Satyabrata Sinha; Christine Mun; Sandeep Jain
Journal:  Ocul Surf       Date:  2019-04-06       Impact factor: 5.033

Review 3.  New and emerging therapies for acute and chronic graft versus host disease.

Authors:  LaQuisa Hill; Amin Alousi; Partow Kebriaei; Rohtesh Mehta; Katayoun Rezvani; Elizabeth Shpall
Journal:  Ther Adv Hematol       Date:  2017-11-28

Review 4.  The search for drug-targetable diagnostic, prognostic and predictive biomarkers in chronic graft-versus-host disease.

Authors:  Hong-Gang Ren; Djamilatou Adom; Sophie Paczesny
Journal:  Expert Rev Clin Immunol       Date:  2018-04-19       Impact factor: 4.473

Review 5.  Aberrant B-cell homeostasis in chronic GVHD.

Authors:  Stefanie Sarantopoulos; Jerome Ritz
Journal:  Blood       Date:  2015-02-02       Impact factor: 22.113

Review 6.  B cells in chronic graft-versus-host disease.

Authors:  Stefanie Sarantopoulos; Bruce R Blazar; Corey Cutler; Jerome Ritz
Journal:  Biol Blood Marrow Transplant       Date:  2014-11-12       Impact factor: 5.742

Review 7.  National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Immune Dysregulation and Pathobiology Working Group Report.

Authors:  Juan Gea-Banacloche; Krishna V Komanduri; Paul Carpenter; Sophie Paczesny; Stefanie Sarantopoulos; Jo-Anne Young; Nahed El Kassar; Robert Q Le; Kirk R Schultz; Linda M Griffith; Bipin N Savani; John R Wingard
Journal:  Biol Blood Marrow Transplant       Date:  2016-10-14       Impact factor: 5.742

8.  SYK inhibitor entospletinib prevents ocular and skin GVHD in mice.

Authors:  Jonathan C Poe; Wei Jia; Julie A Di Paolo; Nancy J Reyes; Ji Yun Kim; Hsuan Su; John S Sundy; Adela R Cardones; Victor L Perez; Benny J Chen; Nelson J Chao; Diana M Cardona; Daniel R Saban; Stefanie Sarantopoulos
Journal:  JCI Insight       Date:  2018-10-04

9.  An aberrant NOTCH2-BCR signaling axis in B cells from patients with chronic GVHD.

Authors:  Jonathan C Poe; Wei Jia; Hsuan Su; Sarah Anand; Jeremy J Rose; Prasanthi V Tata; Amy N Suthers; Corbin D Jones; Pei Fen Kuan; Benjamin G Vincent; Jonathan S Serody; Mitchell E Horwitz; Vincent T Ho; Steven Z Pavletic; Frances T Hakim; Kouros Owzar; Dadong Zhang; Bruce R Blazar; Christian W Siebel; Nelson J Chao; Ivan Maillard; Stefanie Sarantopoulos
Journal:  Blood       Date:  2017-08-29       Impact factor: 22.113

Review 10.  Mechanistic approaches for the prevention and treatment of chronic GVHD.

Authors:  Corey S Cutler; John Koreth; Jerome Ritz
Journal:  Blood       Date:  2016-11-07       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.